NewLink Genetics Corporation appointed Mr. Brian Wiley as Vice President of Business Development. In addition to business development responsibilities, Mr. Wiley will lead the commercialization strategy and pre-commercial activities for the company's HyperAcute Pancreas Immunotherapy, algenpantucel-L. Most recently, Brian was with key roles in both the sale of Gloucester Pharmaceuticals to Celgene Corporation and the purchase of Abraxis Health by Celgene.